Nebivolol is a new selective beta 1-adrenoceptor antagonist with nitric oxide (NO)–releasing
properties. In the present study we have analyzed whether nebivolol affects the …

Background: Nebivolol is a selective β1-adrenergic receptor antagonist that causes a direct
vasodilator effect attributed to the action on vascular nitric oxide (NO). This study aimed to …

Aims Nebivolol is a selective β1‐receptor antagonist with vasodilating properties. In patients
with essential hypertension, we tested the hypothesis that nebivolol increases systemic and …

Background. Nitric oxide (NO) deficiency contributes to chronic kidney disease (CKD)
progression and hypertension. The β-blocker, nebivolol (N), also enhances NO production …

Nebivolol is a new and selective β 1‐adrenergic receptor antagonist whose haemodynamic
profile is different from that of classical β‐blockers. The blood pressure lowering effects of …

β-blockers are among the most widely used drugs in the prevention and treatment of
cardiovascular disease, although they are associated with increased peripheral resistance …

Background Nebivolol is a new β 1-selective adrenergic receptor antagonist with a direct
vasorelaxant effect that involves activation of the l-arginine–nitric oxide (NO) pathway …

Nebivolol is known as a highly selective β1-adrenoceptor antagonist. Based on the reported
vasodilator effect of nebivolol, we examined the cellular mechanisms by which the drug …

Nebivolol (Bystolic®) is a cardioselective beta 1 (β1)‐adrenergic receptor blocker with
endothelium‐dependent vasodilating properties. The endothelium‐dependent relaxation …

Background Vascular endothelial dysfunction may predict future atherosclerosis. Hence, an
antihypertensive agent that reverses endothelial dysfunction and lowers blood pressure …